Lucie Ellis-Taitt
@LucieLEllis
Followers
1K
Following
411
Media
621
Statuses
7K
An estimated 64 priority review vouchers have been issued by the US FDA since the scheme started in 2007. 25 vouchers have been claimed.
insights.citeline.com
Infographic: An estimated 64 priority review vouchers have been issued by the US FDA since the scheme started in 2007. 25 vouchers have been claimed but 39 remain unused. Priority review vouchers do...
0
2
2
'@INFEX_TX CEO Dr Pete Jackson caught up with @LucieLEllis on the @INVIVOnow podcast to discuss the new UK Antibiotics Reimbursement Plan He also spoke about: 📈@INFEX_TX's evolution to clinical-stage biotech 🦠Lessons learnt from #COVID19
#INFX
https://t.co/a0Ctkl7x9C
0
3
2
For In Vivo’s Rising Leaders @LucieLEllis chats with @AmiraBarkal about how she “dreams big and is fearless,” taking down barriers as she leads Pheast’s #CD24 program at the same time as she helps #cancer patients as a resident physician. @INVIVOnow: https://t.co/60G9PzxJ0S
0
1
4
Top 30 leaders: see the list of industry influencers highlighted in the fourth edition of In Vivo's Rising Leaders series.
0
0
2
#LSXworld "We are excited about platforms... @novonordisk is most interested in gene editing deals." Comments from John McDonald.
0
0
1
Interesting chat at #LSXworld this morning. @novonordisk's John McDonald says the company will no longer be a "window shopper". Looking to partner earlier to grow pipeline but staying well away from oncology.
0
1
0
Trial Hot Spot: Australia's Attractions To The Korean Industry https://t.co/MDJqtU1xak
#PharmaScrip
0
1
0
Europe’s Big Pharma Players Begin Tricky 2022 In Style https://t.co/P2LcxG5LbN
0
1
2
China Takes A Bigger Role In The World Pharma Stage https://t.co/Ywhl7jIrby
0
2
0
Elizabeth Jungman: Interpreter Of The FDA’s Policy Crystal Ball https://t.co/CQ7DgzQNX1
0
1
0
After years of the front runners struggling to overcome problems with allogeneic or ‘off-the-shelf’ CAR-T therapies, Caribou Biosciences has unveiled early data which suggest it may just have cracked the challenge with its candidate CB-010.
0
0
0
Roche has suffered a major setback in its goal to lead in a new class of cancer immunotherapies, with the surprise failure of its anti-TIGIT tiragolumab in non-small cell lung cancer.
0
1
1
(1/2) Here's two stories looking at recent filings and approval #pinksheet #pharma: Story 1 is the nearly weekly keeping track: Keeping Track: AZ’s Busy Oncology Biz, Phathom’s Voquezna Approval, And A Trio Of Complete Response Letters
1
1
0
(2/2) Story 2 is a look at breakthrough designations ... #pinksheet #pharma:
0
1
0
2021 Global Biopharma R&D Productivity And Growth Ranking https://t.co/KRRu9LSSTB
0
1
0
Biotech firm @omasstx today completed an impressive $100m series B round. CEO Ros Deegan, one of In Vivo’s 2022 rising leaders, believes the firm’s proprietary technology platform could open the door to an innovative approach to drug discovery.
0
0
1
Bernstein's Ronny Gal is joining $NVS as chief strategy & growth officer from August. Big move!
1
3
34
Another Blow To Aduhelm As Biogen Withdraws EU Filing https://t.co/1Q3ROkO815
#PharmaScrip
0
1
0
3rd annual listing of @INVIVOnow ‘Rising Leaders’ 📰 🏅 @TrellusHealth Co-Founder Laurie Keefer nominated by @LucieLEllis as one of the entrepreneurs and innovators from across the world who represent the next wave of creativity in health care 🏥 https://t.co/aB1oX8z06T
1
2
2